- Raw materials
- Dermatological Agents
- Dermatics
- Desoximetasone
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Desoximetasone API Manufacturers & Suppliers
8 verified results
Commercial-scale Suppliers
Employees: 200+
All certificates
Employees: 50+
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Desoximetasone | CAS No: 382-67-2 | GMP-certified suppliers
A medication that provides targeted relief of inflammatory and itchy corticosteroid‑responsive skin conditions, supporting management of eczema, allergic dermatoses, and localized psoriasis in key markets.
Therapeutic categories
Primary indications
- For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Product Snapshot
- Desoximetasone is a corticosteroid available mainly as topical creams, gels, ointments, and sprays, with additional ophthalmic and oral formulations
- It is used for corticosteroid‑responsive inflammatory and pruritic dermatoses
- It is approved and marketed in the US and Canada
Clinical Overview
Pharmacologically, desoximetasone exhibits anti‑inflammatory, antipruritic, and vasoconstrictive effects characteristic of potent topical corticosteroids. Clinical practice guidelines generally recommend restricting use to short treatment intervals, typically up to two consecutive weeks, and avoiding occlusive dressings to minimize enhanced absorption and associated risks.
The mechanism of action follows established glucocorticoid receptor pathways. After skin penetration, the compound binds cytosolic glucocorticoid receptors, and the resulting complex translocates to the nucleus to modulate transcription. This leads to increased synthesis of phospholipase A2 inhibitory proteins, known as lipocortins, which reduce the release of arachidonic acid from membrane phospholipids. Downstream suppression of prostaglandin and leukotriene formation contributes to reduced inflammation and pruritus.
Absorption is influenced by skin integrity, formulation, and surface area treated. Once absorbed, desoximetasone undergoes metabolic pathways similar to systemically administered corticosteroids, with hepatic biotransformation and renal elimination of metabolites. Systemic exposure is usually low with appropriate topical use, but the risk increases with higher potency agents, large treatment areas, damaged skin, or prolonged application.
Safety considerations include potential for local irritation, skin atrophy, and hypothalamic‑pituitary‑adrenal axis suppression with excessive or long‑term use. Pediatric populations may be more susceptible to systemic effects. Use during pregnancy or lactation requires clinical judgment based on necessity and exposure minimization. Brand formulations have been marketed in various regions, though availability may vary.
For API procurement, sourcing should prioritize verified identity, potency, and impurity control, with particular attention to residual solvents and stability characteristics typical of fluorinated corticosteroids. Compliance with pharmacopeial specifications and supplier transparency in manufacturing controls is essential.
Identification & chemistry
| Generic name | Desoximetasone |
|---|---|
| Molecule type | Small molecule |
| CAS | 382-67-2 |
| UNII | 4E07GXB7AU |
| DrugBank ID | DB00547 |
Pharmacology
| Summary | Desoximetasone is a topical corticosteroid that exerts anti‑inflammatory and antipruritic effects primarily through activation of the glucocorticoid receptor. Receptor binding promotes nuclear transcription changes that induce lipocortins, which inhibit phospholipase A2–mediated release of arachidonic acid and downstream inflammatory mediators. These actions reduce the inflammatory and pruritic components of corticosteroid‑responsive dermatoses. |
|---|---|
| Mechanism of action | The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A<sub>2</sub> inhibitory proteins, collectively called lipocortins. This is achieved first by the drug binding to the glucocorticoid receptors which then translocates into the nucleus and binds to DNA causing various activations and repressions of genes. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub>. |
| Pharmacodynamics | Like other topical corticosteroids, desoximetasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Desoximetasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Glucocorticoid receptor | Humans | agonist |
ADME / PK
| Absorption | Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption. |
|---|---|
| Half-life | The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day. |
| Protein binding | Bound to plasma proteins in varying degrees. |
| Metabolism | Metabolized, primarily in the liver, and then excreted by the kidneys. |
| Route of elimination | Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.Pharmacokinetic studies in men with Desoximetasone Cream USP, 0.25% with tagged desoximetasone showed a total of 5.2% ± 2.9% excretion in urine (4.1% ± 2.3%) and feces (1.1% ± 0.6%) |
Formulation & handling
- Low aqueous solubility and moderate lipophilicity favor topical and ophthalmic formulations requiring solubilizers or suitable emulsifying systems.
- Solid-state stability supports conventional cream, gel, ointment, and suspension formats, with sensitivity mainly to oxidation and light during processing.
- As a small‑molecule corticosteroid, it is not food‑ or peptide‑sensitive, and oral use (where applicable) relies on standard small‑molecule oral excipient strategies for low‑solubility APIs.
Regulatory status
| Lifecycle | The API remains partially protected in the United States, with key patents extending to 2026 and 2028, while earlier protection expired in 2018. With availability in both the US and Canada, the market is progressing toward later‑stage maturity as remaining exclusivities approach expiry. |
|---|
| Markets | Canada, US |
|---|
Supply Chain
| Supply chain summary | Desoximetasone is supplied by several manufacturers, with the original development linked to legacy entities now represented among multiple listed originator and generic producers. The product is available mainly in the US and Canada, indicating a concentrated but established market presence for branded and generic formulations. With one patent expired and two expiring between 2026 and 2028, additional or expanded generic competition is likely as remaining protections lapse. |
|---|
Safety
| Toxicity | Topically applied desoximetasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress). |
|---|
- Systemic absorption may occur with topical exposure, creating risk for glucocorticoid‑class effects such as adrenal axis suppression
- Excess exposure can produce dermal atrophy and other corticosteroid‑related catabolic changes
- Handling should minimize repeated or extensive skin contact to reduce potential for systemic corticosteroid load
Desoximetasone is a type of Dermatics
Dermatics is a prominent subcategory within the pharmaceutical Active Pharmaceutical Ingredient (API) sector. It focuses on the development and production of APIs specifically designed for dermatological applications. These APIs play a crucial role in the formulation of various pharmaceutical products used in the treatment of skin disorders, including creams, ointments, gels, and lotions.
Dermatics APIs are meticulously developed to address specific dermatological conditions such as acne, psoriasis, eczema, fungal infections, and other related ailments. The APIs used in these formulations are carefully selected for their therapeutic efficacy, safety, and compatibility with the skin.
Manufacturers of Dermatics APIs employ rigorous quality control measures to ensure the purity, potency, and stability of their products. These APIs undergo extensive testing to meet stringent regulatory standards and pharmacopoeial guidelines. Additionally, the production processes adhere to Good Manufacturing Practices (GMP) to guarantee consistent quality and minimize the risk of contamination.
With the increasing demand for advanced dermatological treatments, Dermatics APIs are subject to continuous research and development. Newer APIs are being explored to enhance efficacy, minimize side effects, and improve patient compliance. The field of Dermatics APIs is characterized by innovation, as researchers strive to develop novel compounds and delivery systems that address unmet therapeutic needs.
In summary, Dermatics APIs are a vital component of pharmaceutical formulations used in the treatment of skin disorders. They undergo stringent quality control measures and are constantly evolving to provide effective and safe dermatological solutions.
Desoximetasone (Dermatics), classified under Dermatological Agents
Dermatological agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the formulation of various skincare and dermatology products. These APIs are specifically designed to target and treat skin conditions, offering effective solutions for a wide range of dermatological concerns.
Dermatological agents encompass a diverse array of compounds, including corticosteroids, antifungal agents, antibacterials, retinoids, and immunomodulators. Each API within this category possesses unique properties and mechanisms of action, enabling them to address specific skin-related issues.
Corticosteroids, for instance, are potent anti-inflammatory agents commonly used in the treatment of skin conditions like eczema, psoriasis, and dermatitis. Antifungal agents, on the other hand, combat fungal infections such as athlete's foot or ringworm. Antibacterials are effective against bacterial infections, while retinoids promote skin cell turnover and treat acne and photoaging. Immunomodulators regulate the immune response, providing relief from conditions like atopic dermatitis.
The development and application of dermatological APIs involve rigorous research, clinical trials, and regulatory compliance. These APIs are typically integrated into topical creams, ointments, gels, and lotions, ensuring targeted delivery to the affected areas of the skin.
Dermatological agents play a crucial role in the management and treatment of various skin disorders. By harnessing the therapeutic properties of these APIs, pharmaceutical companies can develop innovative skincare products that cater to the diverse needs of individuals seeking effective dermatological solutions.
Desoximetasone API manufacturers & distributors
Compare qualified Desoximetasone API suppliers worldwide. We currently have 8 companies offering Desoximetasone API, with manufacturing taking place in 5 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Cambrex | Producer | Italy | United States | CoA, GMP | 104 products |
| Duchefa Farma B.V. | Distributor | Netherlands | India | CoA, GMP, ISO9001, MSDS | 170 products |
| Farmabios | Producer | Italy | Italy | CoA, GMP, ISO9001, USDMF | 58 products |
| Gonane Pharma | Producer | India | India | BSE/TSE, CoA, GMP, MSDS | 166 products |
| KRKA | Producer | Slovenia | Slovenia | CoA, GMP | 81 products |
| Sanofi | Producer | France | Unknown | CoA, GMP, USDMF | 93 products |
| Sicor | Producer | Italy | Italy | CoA, GMP | 47 products |
| Symbiotec Pharma | Producer | India | India | CoA, GMP, USDMF, WC | 50 products |
When sending a request, specify which Desoximetasone API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Desoximetasone API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Desoximetasone API
Sourcing
What matters most when sourcing GMP-grade Desoximetasone?
Which documents are typically required when sourcing Desoximetasone API?
Which manufacturers are known to produce Desoximetasone API?
How can I request quotes for Desoximetasone API from GMP suppliers?
Is a GMP audit report available for Desoximetasone manufacturers?
How many suppliers offer Desoximetasone API on Pharmaoffer?
Which countries are known to manufacture Desoximetasone API?
Which certifications do suppliers of Desoximetasone usually hold?
Technical
What is Desoximetasone (CAS 382-67-2) used for?
Which therapeutic class does Desoximetasone fall into?
What conditions is Desoximetasone mainly prescribed for?
How does Desoximetasone work?
What should someone know about the safety or toxicity profile of Desoximetasone?
What are important formulation and handling considerations for Desoximetasone as an API?
Is Desoximetasone a small molecule?
Are there special stability concerns for oral Desoximetasone?
Regulatory
Where is Desoximetasone approved or in use globally?
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Desoximetasone procurement?
Is Desoximetasone included in the PRO Data Insights coverage?
Where can I access the API market report for Desoximetasone?
